GlaxoSmithKline and Pfizer are to combine their consumer health care businesses in a joint venture ( JV ) , which will eventually be spun off into a separate company . Their respective painkiller brands , Panadol and Anadin , will now be marketed under the banner of g Consumer Healthcare , with annual sales of £ 9.8bn ( $ 12.7bn ) . GSK will retain 50 % of the new business and have six directors on the board , while Pfizer will have three . GSK Consumer Healthcare is expected to be listed separately on the London stock market over the next three years .
GlaxoSmithKline and Pfizer are to combine their consumer health care units in a joint venture (JV), which will eventually be spun off into a separate company. Their respective painkiller brands, Panadol and Anadin, will now be brought under the banner of GSK Consumer Healthcare, with annual sales of £9.8bn ($12.7bn). GSK will retain 68% of the new business and have six directors on the board, while Pfizer will have three. GSK Consumer Healthcare is expected to be listed separately on the London stock market over the next three years.